KR101188045B1 - 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신 - Google Patents

감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신 Download PDF

Info

Publication number
KR101188045B1
KR101188045B1 KR1020107024618A KR20107024618A KR101188045B1 KR 101188045 B1 KR101188045 B1 KR 101188045B1 KR 1020107024618 A KR1020107024618 A KR 1020107024618A KR 20107024618 A KR20107024618 A KR 20107024618A KR 101188045 B1 KR101188045 B1 KR 101188045B1
Authority
KR
South Korea
Prior art keywords
vaccine
mycobacterium
polypeptide
immunogenic
bcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107024618A
Other languages
English (en)
Korean (ko)
Other versions
KR20100122130A (ko
Inventor
클라우스 아가르드
카리나 빙스보-룬드베르그
피터 안데르센
Original Assignee
스태튼스 세룸 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스태튼스 세룸 인스티튜트 filed Critical 스태튼스 세룸 인스티튜트
Publication of KR20100122130A publication Critical patent/KR20100122130A/ko
Application granted granted Critical
Publication of KR101188045B1 publication Critical patent/KR101188045B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107024618A 2005-06-23 2006-06-20 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신 Expired - Fee Related KR101188045B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500924 2005-06-23
DKPA200500924 2005-06-23
DKPA200501393 2005-10-05
DKPA200501393 2005-10-05
PCT/DK2006/000356 WO2006136162A2 (en) 2005-06-23 2006-06-20 Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087001874A Division KR101035053B1 (ko) 2005-06-23 2006-06-20 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신

Publications (2)

Publication Number Publication Date
KR20100122130A KR20100122130A (ko) 2010-11-19
KR101188045B1 true KR101188045B1 (ko) 2012-10-05

Family

ID=37134239

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107024618A Expired - Fee Related KR101188045B1 (ko) 2005-06-23 2006-06-20 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신
KR1020087001874A Expired - Fee Related KR101035053B1 (ko) 2005-06-23 2006-06-20 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087001874A Expired - Fee Related KR101035053B1 (ko) 2005-06-23 2006-06-20 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신

Country Status (12)

Country Link
US (4) US7968105B2 (enExample)
EP (4) EP2163255B1 (enExample)
JP (2) JP5219808B2 (enExample)
KR (2) KR101188045B1 (enExample)
CN (1) CN102836425B (enExample)
AU (1) AU2006261445B2 (enExample)
BR (1) BRPI0612833A2 (enExample)
CA (2) CA2612900C (enExample)
ES (1) ES2647070T3 (enExample)
IL (3) IL188222A (enExample)
MX (1) MX2007016165A (enExample)
WO (1) WO2006136162A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529931C1 (de) 1995-08-02 1997-04-03 Mannesmann Ag Plattenkokille zur Erzeugung von Strängen aus Stahl
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2008124647A2 (en) * 2007-04-04 2008-10-16 Infectious Disease Research Institute Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
JP5713672B2 (ja) * 2007-04-12 2015-05-07 ジェニファー ライター， 結核のワクチンおよびその使用方法
AU2008271756B2 (en) * 2007-06-29 2012-10-04 Statens Serum Institut The use of monomycolyl glycerol (MMG) as an adjuvant
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
EP2315773B1 (en) 2008-07-25 2016-08-24 GlaxoSmithKline Biologicals S.A. Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
AU2010232180B2 (en) * 2009-03-31 2016-09-22 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
US20120201846A1 (en) * 2009-07-29 2012-08-09 Bernd Helmut Adam Rehm Polymer particles and uses thereof
SG11201500171YA (en) * 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
RU2520737C1 (ru) * 2013-04-25 2014-06-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА pESAT6-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-DBD, ШТАММ Escherichia coli, ХИМЕРНЫЙ БЕЛОК ESAT6-DBD И ИХ ПРИМЕНЕНИЕ
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
RU2539026C1 (ru) * 2013-06-11 2015-01-10 Федеральное государственное бюджетное учреждение "Центральный научно-исследовательский институт туберкулеза" Российской академии медицинских наук РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-CFP10-DBD, РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15 [pREP4, pESAT6-CFP10-DBD], СПОСОБ ПОЛУЧЕНИЯ, ИММОБИЛИЗАЦИИ, КОНЦЕНТРИРОВАНИЯ И ОЧИСТКИ РЕКОМБИНАНТНОГО БЕЛКА ESAT6-CFP10-DBD НА ДЕКСТРАНЕ, РЕКОМБИНАНТНЫЙ БЕЛОК ESAT6-CFP10-DBD И ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК ESAT6-CFP10-DBD
EP3013364B1 (en) 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
EP3092000A1 (en) * 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
CN107970444B (zh) * 2016-10-25 2022-03-01 中国人民解放军第三0九医院 复合佐剂及含有该复合佐剂的疫苗
WO2020249756A1 (en) 2019-06-14 2020-12-17 Statens Serum Institut Fusion proteins for tuberculosis vaccines
CA3196596A1 (en) * 2020-09-23 2022-03-31 The General Hospital Corporation Bcg vaccinations for prevention of covid-19 and other infectious diseases
KR102709729B1 (ko) * 2020-12-04 2024-09-25 주식회사 제넥신 결핵의 예방 또는 치료용 약학적 조성물
CN115598041B (zh) * 2021-07-07 2025-08-19 中国科学院微生物研究所 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用
CN118765203A (zh) 2022-02-21 2024-10-11 史坦恩斯血清研究所 一种新型阳离子佐剂组合物
CN117531001A (zh) * 2023-11-15 2024-02-09 首都医科大学附属北京胸科医院 结核分枝杆菌毒素抗毒素系统及其相关应用
CN117683144A (zh) * 2023-12-08 2024-03-12 上海市公共卫生临床中心 一种结核分支杆菌融合抗原及其亚单位疫苗
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1331C (da) 1897-11-15 Hans Daae Militær- og Skilygte.
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
CN100365017C (zh) * 1994-09-20 2008-01-30 日立化成工业株式会社 肺炎衣原体抗原多肽
JP4091112B2 (ja) 1995-06-07 2008-05-28 コノート ラボラトリーズ インコーポレーテッド リポタンパク質の発現
US20040018574A1 (en) 1998-08-25 2004-01-29 Marcel Behr Molecular differences between species of the M. tuberculosis complex
YU23602A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
WO2002004018A2 (en) 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
CA2445179A1 (en) * 2001-04-23 2002-10-31 Elitra Pharmaceuticals, Inc. Identification of essential genes of aspegillus fumigatus and methods of use
US7393540B2 (en) * 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mol. Microbiol. Vol.43(3):717-731 (2002)

Also Published As

Publication number Publication date
MX2007016165A (es) 2008-03-14
US20120114687A1 (en) 2012-05-10
US8703151B2 (en) 2014-04-22
AU2006261445A1 (en) 2006-12-28
US8101193B2 (en) 2012-01-24
EP2380590A2 (en) 2011-10-26
CN102836425A (zh) 2012-12-26
CA2612900C (en) 2016-08-09
US8293250B2 (en) 2012-10-23
EP2380589A2 (en) 2011-10-26
IL222914A0 (en) 2012-12-31
CA2836319A1 (en) 2006-12-28
JP5219808B2 (ja) 2013-06-26
IL222915A0 (en) 2012-12-31
KR20080027877A (ko) 2008-03-28
KR101035053B1 (ko) 2011-05-19
US7968105B2 (en) 2011-06-28
HK1179855A1 (zh) 2013-10-11
AU2006261445B2 (en) 2011-03-31
IL188222A (en) 2015-11-30
US20090186048A1 (en) 2009-07-23
CA2612900A1 (en) 2006-12-28
BRPI0612833A2 (pt) 2010-11-30
EP1910409A2 (en) 2008-04-16
CN102836425B (zh) 2015-08-19
WO2006136162A3 (en) 2007-11-15
EP2380589A3 (en) 2012-09-12
US20110206713A1 (en) 2011-08-25
WO2006136162A2 (en) 2006-12-28
EP2380590A3 (en) 2012-08-22
IL188222A0 (en) 2008-03-20
EP2163255A1 (en) 2010-03-17
JP2013121959A (ja) 2013-06-20
ES2647070T3 (es) 2017-12-19
EP2163255B1 (en) 2017-08-09
JP2008543890A (ja) 2008-12-04
HK1124071A1 (en) 2009-07-03
KR20100122130A (ko) 2010-11-19
US20130095132A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
KR101035053B1 (ko) 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신
US10519202B2 (en) Tuberculosis TB vaccine to prevent reactivation
EP1523331B1 (en) Therapeutic tb vaccine
US7037510B2 (en) Hybrids of M. tuberculosis antigens
WO2005061534A2 (en) Improved tuberculosis vaccines
CN101248084B (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
AU2013206297A1 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1124071B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1179855B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150904

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20160919

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20170913

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20180830

Year of fee payment: 7

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20190918

Year of fee payment: 8

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20200927

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200927

St.27 status event code: N-4-6-H10-H13-oth-PC1903